PREVENTION AND TREATMENT OF CANCER WITH LKB1 NON-EXPRESSION (DELETION OR MUTATION)

摘要

The present invention relates to a method to prevent or treat cancer with LKB 1 non- expression (deletion or mutation) by administering a EGFR/ErbB2 tyrosine kinase inhibitor, which has grater effect than conventional EGFR/ErbB2 tyrosine kinase inhibitors, or the salt or prodrug thereof to a mammal, a pharmaceutical composition containing at least Ihe EGFR/ErbB2 tyrosine kinase inhibitor for treating or preventing cancer with LKB 1 non-expression (deletion or mutation), use of the EGFR/ErbB2 tyrosine kinase inhibitor for preparing the pharmaceutical composition for treating or preventing cancer with LKB 1 non-expression (deletion or mutation).